| Emily Anderson, CNS | |
|
3000 County Road 42 W Ste 100, Burnsville, MN 55337-4825 | |
| (757) 871-3543 | |
| (808) 460-6151 |
| Full Name | Emily Anderson |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Gerontology |
| Location | 3000 County Road 42 W Ste 100, Burnsville, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306254206 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SG0600X | Clinical Nurse Specialist - Gerontology | 565 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Emily Anderson, CNS 3000 County Road 42 W Ste 100, Burnsville, MN 55337-4825 Ph: (952) 905-0008 | Emily Anderson, CNS 3000 County Road 42 W Ste 100, Burnsville, MN 55337-4825 Ph: (757) 871-3543 |
News Archive
Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism.
The Valspar Corporation, a leading global manufacturer of paints and coatings, and North Dakota State University announced scholarship and research opportunities for students studying coatings and polymeric materials at NDSU.
University of Alabama at Birmingham researchers are exploring ways to wrap pig tissue with a protective coating to ultimately fight diabetes in humans. The nano-thin bilayers of protective material are meant to deter or prevent immune rejection.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).
› Verified 5 days ago
Ms. Ann Marie Mchale, APRN, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 201 E. Nicollet Blvd., Palliative Care And Acute Pain Management, Burnsville, MN 55337 Phone: 952-892-2977 Fax: 952-460-2977 | |
Mrs. Sara Lynn Heit, CNS Clinical Nurse Specialist Medicare: May Accept Medicare Assignments Practice Location: 14551 Judicial Rd Ste 100, Burnsville, MN 55306 Phone: 952-898-5020 | |
Dr. Jane Marie Sulzle, APRN, CNS, DNP Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 675 E Nicollet Blvd Ste 250, Burnsville, MN 55337 Phone: 952-993-3307 | |
Ms. Mary Corinne Beshara, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 201 E Nicollet Blvd, Burnsville, MN 55337 Phone: 952-892-2000 | |
Jodi Ann Wieczorek, AGCNS-BC, A.P.R.N. Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 201 E Nicollet Blvd, Burnsville, MN 55337 Phone: 952-892-2000 | |
Mrs. Danna Dawn Evans Renner, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 675 E Nicollet Blvd Ste 100, Burnsville, MN 55337 Phone: 952-892-7190 Fax: 952-892-7956 |